Thymosin beta 4 (TB4) accelerates wound healing

[Guest guest]

NIH Scientist Reports Wound Healing Effects of TB4; Data Presented at

15th Annual Meeting of the Wound Healing Society

BETHESDA, Md.--(BUSINESS WIRE)--May 19, 2005--RegeneRx

Biopharmaceuticals, Inc. (AMEX:RGN) (www.regenerx.com) reported today

that Dr. Hynda Kleinman, Chief of the Laboratory of Cell Biology at

the National Institutes of Health's (NIH) Dental and Craniofacial

Research Institute in Bethesda, MD, presented data showing how

Thymosin beta 4 (TB4) accelerates wound healing, as well as the

stimulation of hair follicles in laboratory animals. In her

presentation today at the 15th Annual Meeting of the Wound Healing

Society in Chicago, IL, Dr. Kleinman emphasized TB4's ability to up-

regulate or " turn on " two genes, zyxin and laminin-5, both of which

are important for cellular adhesion and cell migration, two key

biological activities necessary for successful wound healing.

Dr. Kleinman also presented confirmatory data indicating TB4's

ability to enter the nucleus of the cell due to the presence of

actin, a major cell-building protein to which TB4 readily attaches.

According to Dr. Allan L. Goldstein, Chairman of the Department of

Biochemistry and Molecular Biology at the Washington

University School of Medicine in Washington, DC and RegeneRx's Chief

Scientific Advisor, " The ability of TB4 to enter the cell nucleus

offers a very interesting possibility that it could be used as a

carrier or 'chaperone molecule' to allow manipulation of cells at the

nuclear level. This capability could open up a whole new avenue for

delivering specialized chemotherapeutic agents, or other drugs, to

cells in a very efficient and targeted manner and further broadens

the possible uses of TB4. "

RegeneRx Biopharmaceuticals, Inc.

RegeneRx (www.regenerx.com) is a biopharmaceutical company developing

TB4 as a platform technology for the treatment of acute and chronic

wounds and for a variety of human diseases involving tissue and organ

repair under an exclusive world-wide license from the National

Institutes of Health. The company holds over fifty world-wide patents

and patent applications related to dermal, ophthalmic, and internal

wounds and tissue repair, including the prevention and treatment

cardiac and neurological injuries, as well as patents related to the

treatment of septic shock. RegeneRx has received clearance from the

U.S. FDA for its first three Phase II dermal wound healing clinical

trials and has also targeted ophthalmic and cardiac wound healing as

part of its ongoing clinical development program.